Die Chemesis-Tochter Natural Ventures hat VividGro-LED-Beleuchtungskörper installiert und konnte die Anbaukapazität ihrer Betriebsanlage verdoppeln sowie die Energiekosten um 40 % senken

16. September 2019, Vancouver, BC – Chemesis International Inc. (CSE: CSI) (OTC: CADMF) (FRA: CWAA) (das „Unternehmen“ oder „Chemesis“) ist stolz darauf bekannt geben zu können, dass die Installation der VividGro-LED-Beleuchtung sowie der Einrichtungen zur Kontrolle und Steuerung der klimatischen Bedingungen im Cannabisanbaubetrieb Natural Ventures in Puerto Rico nunmehr abgeschlossen ist. Dank dem bereits angekündigten Partnerschaftsabkommen ist es dem Unternehmen gelungen, seine Anbaufläche zu verdoppeln und den Energie- und Kostenbedarf des Betriebs drastisch zu senken. Die während der Installation von VividGro durchgeführten detaillierten Aufzeichnungen sind Teil einer Fallstudie. Die Ergebnisse können hier eingesehen werden.

Chemesis now operates eleven dispensaries in Puerto Rico & the United States, with an additional seven dispensaries invarious stages of development

VANCOUVER, British Columbia, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Chemesis International Inc. (CSE: CSI) (OTC: CADMF) (FRA: CWAA) (the “Company” or “Chemesis”), announces that its subsidiary, Natural Ventures PR LLC (“Natural Ventures”), has entered into an agreement to purchase (the “Acquisition”) three cannabis dispensary operations (the “Dispensaries”) in Puerto Rico from Caribbean Green LLC (“Caribbean Green”) in exchange for $1.3 million USD in cash over 24 months. The Dispensaries are currently operating under the Caribbean Green brand and will generate approximately $3,600,000 USD in revenues for calendar 2019.

Chemesis' subsidiary Natural Ventures will continue to work with First Medical Cannabis to cultivate, manufacture, distribute, & retail CBD products

Natural Ventures will plant the initial crop in the coming weeks

VANCOUVER, British Columbia, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Chemesis International Inc. (CSE: CSI) (OTC: CADMF) (FRA: CWAA) (the "Company" or "Chemesis"), is proud to announce its subsidiary, Natural Ventures, in conjunction with First Medical Cannabis LLC, ("First Medical") through its previously announced partnership, has received one of the first hemp cultivation and processing licenses in Puerto Rico. The Company has now finished the climatization of seeds, and will begin planting an initial high potency hemp CBD crop in the coming weeks.

After completing installation, permitting and the testing phase, Chemesis has begun accepting orders of QuickStripTM Oral Thin Strips

VANCOUVER, British Columbia, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Chemesis International Inc. (CSE: CSI) (OTC: CADMF) (FRA: CWAA) (the “Company” or “Chemesis”), is proud to announce its subsidiary, Natural Ventures, has completed the installation, permitting, and testing phase of its QuickStrip™ oral thin strip production equipment. The Company has completed the previously announced commercialization strategy, and has begun accepting orders for QuickStrip for immediate distribution across Puerto Rico and the United States.

TORONTO, Sept. 4, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announced today that it has commenced construction of a 9,800 m² (105,486 sq.ft) cultivation and processing facility in Juan Lacaze, Uruguay. With a production capacity of 17 tons per year, the Company's investment in this state-of-the-art facility represents a significant increase in Khiron's total production capacity, strengthening its ability to export and supply cannabis to key international markets, including Brazil and Europe. Construction is underway and is scheduled for completion in mid Q3 2020.